Cryptococcus antigens and immune responses: Implications for a vaccine

Expert Review of Vaccines

Volumn 12, Issue 11, 2013, Pages 1261-1272

  Chaturvedi, Ashok K ^a   Wormley Jr , Floyd L ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

Cryptococcosis; Cryptococcus gattii; Cryptococcus neoformans; Cryptococcus vaccine; fungal antigens; fungal pathogenesis; fungal vaccines; host fungal interactions; immunotherapy

Indexed keywords

AMPHOTERICIN B; ANTIGEN; BISMUTH; DIPHTHERIA TOXOID CRM197; EFUNGUMAB; IMMUNOSUPPRESSIVE AGENT; RHENIUM;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CRYPTOCOCCOSIS; CRYPTOCOCCUS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; EPIDEMIC; GRAFT REJECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANTIGENS, FUNGAL; CRYPTOCOCCOSIS; CRYPTOCOCCUS; FUNGAL VACCINES; HUMANS; IMMUNOCOMPROMISED HOST; WORLD HEALTH;

EID: 84887359715     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2013.840094     Document Type: Review

References (164)

1. Cryptococcus: From Human Pathogen to Model Yeast. Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A (Eds). ASM Press, Washington, DC, USA (2010
2. Vibhagool A, Sungkanuparph S, Mootsikapun P et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: A prospective, multicenter, randomized study. Clin. Infect. Dis. 36(10), 1329-1331 (2003
3. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23(4), 525-530 (2009
4. Bozzette SA, Larsen RA, Chiu J et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N. Engl. J. Med. 324(9), 580-584 (1991
5. Aberg JA, Price RW, Heeren DM, Bredt B. A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapy. J. Infect. Dis. 185(8), 1179-1182 (2002
6. Dromer F, Mathoulin-Pelissier S, Fontanet A, Ronin O, Dupont B, Lortholary O. Epidemiology of HIV-Associated cryptococcosis in France (1985-2001): Comparison of the pre-And post-HAART eras. AIDS 18(3), 555-562 (2004
7. Singh N, Perfect Jr. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect. Dis. 7(6), 395-401 (2007
8. Chen SC, Korman TM, Slavin MA et al. Antifungal Therapy and Management of Complications of Cryptococcosis due to Cryptococcus gattii. Clin. Infect. Dis. 57(4), 543-551 (2013
9. Sungkanuparph S, Filler SG, Chetchotisakd P et al. Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: A prospective multicenter study. Clin. Infect. Dis. 49(6), 931-934 (2009
10. Singh N, Lortholary O, Alexander BD et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. Clin. Infect. Dis. 40(12), 1756-1761 (2005
11. Singh N, Dromer F, Perfect JR, Lortholary O. Cryptococcosis in solid organ transplant recipients: Current state of the science. Clin. Infect. Dis. 47(10), 1321-1327 (2008
12. Husain S, Wagener MM, Singh N. Cryptococcus neoformans infection in organ transplant recipients: Variables influencing clinical characteristics and outcome. Emerg. Infect. Dis. 7(3), 375-381 (2001
13. Pappas PG, Alexander BD, Andes DR et al. Invasive fungal infections among organ transplant recipients: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin. Infect. Dis. 50(8), 1101-1111 (2010
14. Powderly WG. Cryptococcal meningitis and AIDS. Clin. Infect. Dis. 17(5), 837-842 (1993
15. Saag MS, Graybill RJ, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis. 30(4), 710-718 (2000
16. Van Der Horst CM, Saag MS, Cloud GA et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N. Engl. J. Med. 337(1), 15-21 (1997
17. Chau TT, Mai NH, Phu NH et al. A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam-high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease. BMC Infect. Dis. 10, 199 (2010
18. Chen J, Varma A, Diaz MR, Litvintseva AP, Wollenberg KK, Kwon-Chung KJ. Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China. Emerg. Infect. Dis. 14(5), 755-762 (2008
19. Jarvis JN, Harrison TS. Pulmonary cryptococcosis. Semin. Respir. Crit. Care Med. 29(2), 141-150 (2008
20. Litvintseva AP, Thakur R, Reller LB, Mitchell TG. Prevalence of clinical isolates of Cryptococcus gattii serotype C among patients with AIDS in Sub-Saharan Africa. J. Infect. Dis. 192(5), 888-892 (2005
21. Hagen F, Colom MF, Swinne D et al. Autochthonous and dormant Cryptococcus gattii infections in Europe. Emerg. Infect. Dis. 18(10), 1618-1624 (2012
22. Kwon-Chung KJ, Bennett JE. Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am. J. Epidemiol. 120(1), 123-130 (1984
23. Galanis E, Macdougall L. Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999-2007. Emerg. Infect. Dis. 16(2), 251-257 (2010
24. Datta K, Bartlett KH, Marr KA. Cryptococcus gattii: Emergence in Western North America: Exploitation of a Novel Ecological Niche. Interdiscip. Perspect. Infect. Dis. 2009, 176532 (2009
25. Datta K, Bartlett KH, Baer R et al. Spread of Cryptococcus gattii into Pacific Northwest region of the United States. Emerg. Infect. Dis. 15(8), 1185-1191 (2009
26. Emergence of Cryptococcus gattii-Pacific Northwest, 2004-2010. MMWR Morb. Mortal. Wkly Rep. 59(28), 865-868 (2010
27. Byrnes EJ 3rd, Li W, Lewit Y et al. First reported case of Cryptococcus gattii in the Southeastern USA: Implications for travel-Associated acquisition of an emerging pathogen. PLoS ONE 4(6), e5851 (2009
28. Walraven CJ, Gerstein W, Hardison SE et al. Fatal disseminated Cryptococcus gattii infection in New Mexico. PLoS ONE 6(12), e28625 (2011
29. Mcculloh RJ, Phillips R, Perfect JR, Byrnes EJ 3rd, Heitman J, Dufort E. Cryptococcus gattii genotype VGI infection in New England. Pediatr. Infect. Dis. J. 30(12), 1111-1114 (2011
30. Mitchell TG, Perfect Jr. Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 8(4), 515-548 (1995
31. Goldman DL, Khine H, Abadi J et al. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 107(5), E66 (2001
32. Abadi J, Pirofski L. Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without human immunodeficiency virus infection. J. Infect. Dis. 180(3), 915-919 (1999
33. Giles SS, Dagenais TR, Botts MR, Keller NP, Hull CM. Elucidating the pathogenesis of spores from the human fungal pathogen Cryptococcus neoformans. Infect. Immun. 77(8), 3491-3500 (2009
34. Velagapudi R, Hsueh YP, Geunes-Boyer S, Wright JR, Heitman J. Spores as infectious propagules of Cryptococcus neoformans. Infect. Immun. 77(10), 4345-4355 (2009
35. Callejas A, Ordonez N, Rodriguez MC, Castaneda E. First isolation of Cryptococcus neoformans var. gattii, serotype C, from the environment in Colombia. Med. Mycol. 36(5), 341-344 (1998
36. Chakrabarti A, Jatana M, Kumar P, Chatha L, Kaushal A, Padhye AA. Isolation of Cryptococcus neoformans var. gattii from Eucalyptus camaldulensis in India. J. Clin. Microbiol. 35(12), 3340-3342 (1997
37. Pfeiffer TJ, Ellis DH. Environmental isolation of Cryptococcus neoformans var. gattii from Eucalyptus tereticornis. J. Med. Vet. Mycol. 30(5), 407-408 (1992
38. Kidd SE, Chow Y, Mak S et al. Characterization of environmental sources of the human and animal pathogen Cryptococcus gattii in British Columbia, Canada, and the Pacific Northwest of the United States. Appl. Environ. Microbiol. 73(5), 1433-1443 (2007
39. Nosanchuk JD, Shoham S, Fries BC, Shapiro DS, Levitz SM, Casadevall A. Evidence of zoonotic transmission of Cryptococcus neoformans from a pet cockatoo to an immunocompromised patient. Ann. Intern. Med. 132(3), 205-208 (2000
40. Shrestha RK, Stoller JK, Honari G, Procop GW, Gordon SM. Pneumonia due to Cryptococcus neoformans in a patient receiving infliximab: Possible zoonotic transmission from a pet cockatiel. Respir. Care 49(6), 606-608 (2004
41. Spitzer ED, Spitzer SG, Freundlich LF, Casadevall A. Persistence of initial infection in recurrent Cryptococcus neoformans meningitis. Lancet 341(8845), 595-596 (1993
42. Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evidence for dormant Cryptococcus neoformans infection. J. Clin. Microbiol. 37(10), 3204-3209 (1999
43. Staib F, Seibold M, Láge M. Persistence of Cryptococcus neoformans in seminal fluid and urine under itraconazole treatment. The urogenital tract (prostate) as a niche for Cryptococcus neoformans. Mycoses 33(7-8), 369-373 (1990
44. Ndimbie OK, Dekker A, Martinez AJ, Dixon B. Prostatic sequestration of Cryptococcus neoformans in immunocompromised persons treated for cryptococcal meningoencephalitis. Histol. Histopathol. 9(4), 643-648 (1994
45. Almeida AM, Matsumoto MT, Baeza LC et al. Molecular typing and antifungal susceptibility of clinical sequential isolates of Cryptococcus neoformans from Sao Paulo State, Brazil. FEMS Yeast. Res. 7(1), 152-164 (2007
46. Mody CH, Wood CJ, Syme RM, Spurrell JC. The cell wall and membrane of Cryptococcus neoformans possess a mitogen for human T lymphocytes. Infect. Immun. 67(2), 936-941 (1999
47. Chang CC, Crane M, Zhou J et al. HIV and co-infections. Immunol. Rev. 254(1), 114-142 (2013
48. Pappas PG. Cryptococcal infections in non-hiv-infected patients. Trans. Am. Clin. Climatol. Assoc. 124, 61-79 (2013
49. Chayakulkeeree M, Perfect Jr. Cryptococcosis. Infect. Dis. Clin. North Am. 20(3), 507-544, v-vi (2006
50. Wozniak KL, Ravi S, Macias S et al. Insights into the mechanisms of protective immunity against Cryptococcus neoformans infection using a mouse model of pulmonary cryptococcosis. PLoS ONE 4(9), e6854 (2009
51. Olszewski MA, Zhang Y, Huffnagle GB. Mechanisms of cryptococcal virulence and persistence. Future Microbiol. 5(8), 1269-1288 (2010
52. Hole CR, Wormley FL Jr. Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: Lessons learned from animal models. Front. Microbiol. 3, 291 (2012
53. Hill JO. CD4+ T cells cause multinucleated giant cells to form around Cryptococcus neoformans and confine the yeast within the primary site of infection in the respiratory tract. J. Exp. Med. 175(6), 1685-1695 (1992
54. Mody CH, Lipscomb MF, Street NE, Toews GB. Depletion of CD4+ (L3T4+) lymphocytes in vivo impairs murine host defense to Cryptococcus neoformans. J. Immunol. 144(4), 1472-1477 (1990
55. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8(12), 958-969 (2008
56. Muller U, Stenzel W, Kohler G et al. IL-13 induces disease-promoting type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with Cryptococcus neoformans. J. Immunol. 179(8), 5367-5377 (2007
57. Arora S, Hernandez Y, Erb-Downward JR, Mcdonald RA, Toews GB, Huffnagle GB. Role of IFN-gamma in regulating T2 immunity and the development of alternatively activated macrophages during allergic bronchopulmonary mycosis. J. Immunol. 174(10), 6346-6356 (2005
58. Osterholzer JJ, Milam JE, Chen GH, Toews GB, Huffnagle GB, Olszewski MA. Role of dendritic cells and alveolar macrophages in regulating early host defense against pulmonary infection with Cryptococcus neoformans. Infect. Immun. 77(9), 3749-3758 (2009
59. Zhang Y, Wang F, Tompkins KC et al. Robust Th1 and Th17 immunity supports pulmonary clearance but cannot prevent systemic dissemination of highly virulent Cryptococcus neoformans H99. Am. J. Pathol. 175(6), 2489-2500 (2009
60. Wozniak KL, Hardison SE, Kolls JK, Wormley FL. Role of IL-17A on resolution of pulmonary C. neoformans infection. PLoS ONE 6(2), e17204 (2011
61. Hardison SE, Wozniak KL, Kolls JK, Wormley FL Jr. Interleukin-17 is not required for classical macrophage activation in a pulmonary mouse model of Cryptococcus neoformans infection. Infect. Immun. 78(12), 5341-5351 (2010
62. Hardison SE, Herrera G, Young ML, Hole CR, Wozniak KL, Wormley FL Jr. Protective immunity against pulmonary cryptococcosis is associated with STAT1-mediated classical macrophage activation. J. Immunol. 189(8), 4060-4068 (2012
63. Wozniak KL, Vyas JM, Levitz SM. In vivo role of dendritic cells in a murine model of pulmonary cryptococcosis. Infect. Immun. 74(7), 3817-3824 (2006
64. Lewis KL, Reizis B. Dendritic cells: Arbiters of immunity and immunological tolerance. Cold Spring Harb. Perspect. Biol. 4(8), a007401 (2012
65. Geijtenbeek TB, Den Dunnen J, Gringhuis SI. Pathogen recognition by DC-SIGN shapes adaptive immunity. Future Microbiol. 4(7), 879-890 (2009
66. Colonna M, Pulendran B, Iwasaki A. Dendritic cells at the host-pathogen interface. Nat. Immunol. 7(2), 117-120 (2006
67. Jain AV, Zhang Y, Fields WB et al. Th2 but not Th1 immune bias results in altered lung functions in a murine model of pulmonary Cryptococcus neoformans infection. Infect. Immun. 77(12), 5389-5399 (2009
68. Osterholzer JJ, Curtis JL, Polak T et al. CCR2 mediates conventional dendritic cell recruitment and the formation of bronchovascular mononuclear cell infiltrates in the lungs of mice infected with Cryptococcus neoformans. J. Immunol. 181(1), 610-620 (2008
69. Huang C, Nong SH, Mansour MK, Specht CA, Levitz SM. Purification and characterization of a second immunoreactive mannoprotein from Cryptococcus neoformans that stimulates T-Cell responses. Infect. Immun. 70(10), 5485-5493 (2002
70. Huffnagle GB, Lipscomb MF, Lovchik JA, Hoag KA, Street NE. The role of CD4+ and CD8+ T cells in the protective inflammatory response to a pulmonary cryptococcal infection. J. Leukoc. Biol. 55(1), 35-42 (1994
71. Wozniak KL, Young ML, Wormley FL Jr. Protective immunity against experimental pulmonary cryptococcosis in T cell-depleted mice. Clin. Vaccine Immunol. 18(5), 717-723 (2011
72. Wormley FL Jr, Perfect JR, Steele C, Cox GM. Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain. Infect. Immun. 75(3), 1453-1462 (2007
73. Iseki M, Anzo M, Yamashita N, Matsuo N. Hyper-IgM immunodeficiency with disseminated cryptococcosis. Acta Paediatr. 83(7), 780-782 (1994
74. Neto Rda J, Guimaraes MC, Moya MJ, Oliveira FR, Louzada PL Jr, Martinez R. [Hypogammaglobulinemia as risk factor for Cryptococcus neoformans infection: Report of 2 cases]. Rev. Soc. Bras. Med. Trop. 33(6), 603-608 (2000
75. Antachopoulos C, Walsh TJ, Roilides E. Fungal infections in primary immunodeficiencies. Eur. J. Pediatr. 166(11), 1099-1117 (2007
76. Gupta S, Ellis M, Cesario T, Ruhling M, Vayuvegula B. Disseminated cryptococcal infection in a patient with hypogammaglobulinemia and normal T cell functions. Am. J. Med. 82(1), 129-131 (1987
77. Mukherjee S, Lee SC, Casadevall A. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect. Immun. 63(2), 573-579 (1995
78. Bolanos B, Mitchell TG. Phagocytosis of Cryptococcus neoformans by rat alveolar macrophages. J. Med. Vet. Mycol. 27(4), 203-217 (1989
79. Subramaniam KS, Datta K, Quintero E, Manix C, Marks MS, Pirofski LA. The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans. J. Immunol. 184(10), 5755-5767 (2010
80. Miller MF, Mitchell TG, Storkus WJ, Dawson Jr. Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody. Infect. Immun. 58(3), 639-645 (1990
81. Diamond RD. Antibody-dependent killing of Cryptococcus neoformans by human peripheral blood mononuclear cells. Nature 247(437), 148-150 (1974
82. Murphy JW, Mcdaniel DO. In vitro reactivity of natural killer (NK) cells against Cryptococcus neoformans. J. Immunol. 128(4), 1577-1583 (1982
83. Dromer F, Charreire J, Contrepois A, Carbon C, Yeni P. Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect. Immun. 55(3), 749-752 (1987
84. Goldman DL, Lee SC, Casadevall A. Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect. Immun. 63(9), 3448-3453 (1995
85. Mukherjee J, Scharff MD, Casadevall A. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect. Immun. 60(11), 4534-4541 (1992
86. Mukherjee S, Lee S, Mukherjee J, Scharff MD, Casadevall A. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect. Immun. 62(3), 1079-1088 (1994
87. Mukherjee J, Pirofski LA, Scharff MD, Casadevall A. Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc. Natl Acad. Sci. USA 90(8), 3636-3640 (1993
88. Feldmesser M, Mednick A, Casadevall A. Antibody-mediated protection in murine Cryptococcus neoformans infection is associated with pleotrophic effects on cytokine and leukocyte responses. Infect. Immun. 70(3), 1571-1580 (2002
89. Subramaniam KS, Datta K, Marks MS, Pirofski LA. Improved survival of mice deficient in secretory immunoglobulin M following systemic infection with Cryptococcus neoformans. Infect. Immun. 78(1), 441-452 (2010
90. Mukherjee J, Nussbaum G, Scharff MD, Casadevall A. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J. Exp. Med. 181(1), 405-409 (1995
91. Yuan RR, Spira G, Oh J, Paizi M, Casadevall A, Scharff MD. Isotype switching increases efficacy of antibody protection against Cryptococcus neoformans infection in mice. Infect. Immun. 66(3), 1057-1062 (1998
92. Casadevall A. Antibody immunity and invasive fungal infections. Infect. Immun. 63(11), 4211-4218 (1995
93. Nussbaum G, Yuan R, Casadevall A, Scharff MD. Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans. J. Exp. Med. 183(4), 1905-1909 (1996
94. Yuan R, Casadevall A, Spira G, Scharff MD. Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. J. Immunol. 154(4), 1810-1816 (1995
95. Taborda CP, Casadevall A. Immunoglobulin M efficacy against Cryptococcus neoformans: Mechanism, dose dependence, and prozone-like effects in passive protection experiments. J. Immunol. 166(3), 2100-2107 (2001
96. Taborda CP, Rivera J, Zaragoza O, Casadevall A. More is not necessarily better: Prozone-like effects in passive immunization with IgG. J. Immunol. 170(7), 3621-3630 (2003
97. Zaragoza O, Alvarez M, Telzak A, Rivera J, Casadevall A. The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response. Infect. Immun. 75(6), 2729-2739 (2007
98. Rivera J, Casadevall A. Mouse genetic background is a major determinant of isotype-related differences for antibody-mediated protective efficacy against Cryptococcus neoformans. J. Immunol. 174(12), 8017-8026 (2005
99. Yuan RR, Casadevall A, Oh J, Scharff MD. T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc. Natl Acad. Sci. USA 94(6), 2483-2488 (1997
100. Beenhouwer DO, Shapiro S, Feldmesser M, Casadevall A, Scharff MD. Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans. Infect. Immun. 69(10), 6445-6455 (2001
101. Beenhouwer DO, Yoo EM, Lai CW, Rocha MA, Morrison SL. Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection. Infect. Immun. 75(3), 1424-1435 (2007
102. Mcclelland EE, Nicola AM, Prados-Rosales R, Casadevall A. Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism. J. Clin. Invest. 120(4), 1355-1361 (2010
103. Brena S, Cabezas-Olcoz J, Moragues MD et al. Fungicidal monoclonal antibody C7 interferes with iron acquisition in Candida albicans. Antimicrob. Agents Chemother. 55(7), 3156-3163 (2011
104. Casadevall A, Pirofski LA. Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma. Infect. Immun. 75(11), 5074-5078 (2007
105. Martinez LR, Casadevall A. Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy. Infect. Immun. 73(10), 6350-6362 (2005
106. Zaragoza O, Rodrigues ML, De Jesus M, Frases S, Dadachova E, Casadevall A. The capsule of the fungal pathogen Cryptococcus neoformans. Adv. Appl. Microbiol. 68, 133-216 (2009
107. Mclean GR, Torres M, Elguezabal N, Nakouzi A, Casadevall A. Isotype can affect the fine specificity of an antibody for a polysaccharide antigen. J. Immunol. 169(3), 1379-1386 (2002
108. Goldblatt D. Conjugate vaccines. Clin. Exp. Immunol. 119(1), 1-3 (2000
109. Chow SK, Casadevall A. Evaluation of Cryptococcus neoformans galactoxylomannanprotein conjugate as vaccine candidate against murine cryptococcosis. Vaccine 29(10), 1891-1898 (2011
110. Devi SJ, Schneerson R, Egan W et al. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: Synthesis, characterization, and immunogenicity. Infect. Immun. 59(10), 3700-3707 (1991
111. Casadevall A, Mukherjee J, Devi SJ, Schneerson R, Robbins JB, Scharff MD. Antibodies elicited by a Cryptococcus neoformans-Tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J. Infect. Dis. 165(6), 1086-1093 (1992
112. Zhong Z, Pirofski LA. Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies. Infect. Immun. 64(9), 3446-3450 (1996
113. Zhong Z, Pirofski LA. Antifungal activity of a human antiglucuronoxylomannan antibody. Clin. Diagn. Lab. Immunol. 5(1), 58-64 (1998
114. Devi SJ. Preclinical efficacy of a glucuronoxylomannan-Tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine 14(9), 841-844 (1996
115. Nussbaum G, Anandasabapathy S, Mukherjee J, Fan M, Casadevall A, Scharff MD. Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice. Infect. Immun. 67(9), 4469-4476 (1999
116. Fleuridor R, Zhong Z, Pirofski L. A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis. J. Infect. Dis. 178(4), 1213-1216 (1998
117. Rivera J, Mukherjee J, Weiss LM, Casadevall A. Antibody efficacy in murine pulmonary Cryptococcus neoformans infection: A role for nitric oxide. J. Immunol. 168(7), 3419-3427 (2002
118. Zhang H, Zhong Z, Pirofski LA. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody. Infect. Immun. 65(4), 1158-1164 (1997
119. Fleuridor R, Lees A, Pirofski L. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection. J. Immunol. 166(2), 1087-1096 (2001
120. Datta K, Lees A, Pirofski LA. Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan. Clin. Vaccine Immunol. 15(8), 1176-1187 (2008
121. Maitta RW, Datta K, Pirofski LA. Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan. Vaccine 22(29-30), 4062-4068 (2004
122. May RJ, Beenhouwer DO, Scharff MD. Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates: Implications for vaccine development. J. Immunol. 171(9), 4905-4912 (2003
123. Casadevall A, Cleare W, Feldmesser M et al. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob. Agents Chemother. 42(6), 1437-1446 (1998
124. Larsen RA, Pappas PG, Perfect J et al. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob. Agents Chemother. 49(3), 952-958 (2005
125. Westin Kwon K, Lendvai N, Morrison S, Trinh KR, Casadevall A. Biological activity of a mouse-human chimeric immunoglobulin G2 antibody to Cryptococcus neoformans polysaccharide. Clin. Diagn. Lab. Immunol. 9(1), 201-204 (2002
126. Bryan RA, Jiang Z, Howell RC et al. Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection. J. Infect. Dis. 202(4), 633-637 (2010
127. Dadachova E, Nakouzi A, Bryan RA, Casadevall A. Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc. Natl Acad. Sci. USA 100(19), 10942-10947 (2003
128. Rosas AL, Nosanchuk JD, Casadevall A. Passive immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal Cryptococcus neoformans infection. Infect. Immun. 69(5), 3410-3412 (2001
129. Rachini A, Pietrella D, Lupo P et al. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect. Immun. 75(11), 5085-5094 (2007
130. Nooney L, Matthews RC, Burnie JP. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagn. Microbiol. Infect. Dis. 51(1), 19-29 (2005
131. Rodrigues ML, Shi L, Barreto-Bergter E et al. Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection. Clin. Vaccine Immunol. 14(10), 1372-1376 (2007
132. Torosantucci A, Bromuro C, Chiani P et al. A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. 202(5), 597-606 (2005
133. Matthews RC, Rigg G, Hodgetts S et al. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob. Agents Chemother. 47(7), 2208-2216 (2003
134. Pachl J, Svoboda P, Jacobs F et al. A randomized, blinded, multicenter trial of lipid-Associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin. Infect. Dis. 42(10), 1404-1413 (2006
135. Murphy JW, Schafer F, Casadevall A, Adesina A. Antigen-induced protective and nonprotective cell-mediated immune components against Cryptococcus neoformans. Infect. Immun. 66(6), 2632-2639 (1998
136. Yauch LE, Lam JS, Levitz SM. Direct inhibition of T-cell responses by the Cryptococcus capsular polysaccharide glucuronoxylomannan. PLoS Pathog. 2(11), e120 (2006
137. Murphy JW, Mosley RL, Cherniak R, Reyes GH, Kozel TR, Reiss E. Serological, electrophoretic, and biological properties of Cryptococcus neoformans antigens. Infect. Immun. 56(2), 424-431 (1988
138. Hoy JF, Murphy JW, Miller GG. T cell response to soluble cryptococcal antigens after recovery from cryptococcal infection. J. Infect. Dis. 159(1), 116-119 (1989
139. Levitz SM, North EA. Lymphoproliferation and cytokine profiles in human peripheral blood mononuclear cells stimulated by Cryptococcus neoformans. J. Med. Vet. Mycol. 35(4), 229-236 (1997
140. Pitzurra L, Perito S, Baldelli F, Bistoni F, Vecchiarelli A. Humoral response against Cryptococcus neoformans mannoprotein antigens in HIV-infected patients. Clin. Exp. Immunol. 133(1), 91-96 (2003
141. Levitz SM, Specht CA. The molecular basis for the immunogenicity of Cryptococcus neoformans mannoproteins. FEMS Yeast. Res. 6(4), 513-524 (2006
142. Levitz SM, Nong S, Mansour MK, Huang C, Specht CA. Molecular characterization of a mannoprotein with homology to chitin deacetylases that stimulates T cell responses to Cryptococcus neoformans. Proc. Natl Acad. Sci. USA 98(18), 10422-10427 (2001
143. Specht CA, Nong S, Dan JM, Lee CK, Levitz SM. Contribution of glycosylation to T cell responses stimulated by recombinant Cryptococcus neoformans mannoprotein. J. Infect. Dis. 196(5), 796-800 (2007
144. Biondo C, Messina L, Bombaci M et al. Characterization of two novel cryptococcal mannoproteins recognized by immune sera. Infect. Immun. 73(11), 7348-7355 (2005
145. Pietrella D, Corbucci C, Perito S, Bistoni G, Vecchiarelli A. Mannoproteins from Cryptococcus neoformans promote dendritic cell maturation and activation. Infect. Immun. 73(2), 820-827 (2005
146. Dan JM, Wang JP, Lee CK, Levitz SM. Cooperative stimulation of dendritic cells by Cryptococcus neoformans mannoproteins and CpG oligodeoxynucleotides. PLoS ONE 3(4), e2046 (2008
147. Coenjaerts FE, Walenkamp AM, Mwinzi PN et al. Potent inhibition of neutrophil migration by cryptococcal mannoprotein-4-induced desensitization. J. Immunol. 167(7), 3988-3995 (2001
148. Mansour MK, Yauch LE, Rottman JB, Levitz SM. Protective efficacy of antigenic fractions in mouse models of cryptococcosis. Infect. Immun. 72(3), 1746-1754 (2004
149. Eigenheer RA, Jin Lee Y, Blumwald E, Phinney BS, Gelli A. Extracellular glycosylphosphatidylinositol-Anchored mannoproteins and proteases of Cryptococcus neoformans. FEMS Yeast. Res. 7(4), 499-510 (2007
150. Li Pira G, Ivaldi F, Moretti P, Manca F. High throughput T epitope mapping and vaccine development. J. Biomed. Biotechnol. 2010, 325720 (2010
151. Pietrella D, Mazzolla R, Lupo P et al. Mannoprotein from Cryptococcus neoformans promotes T-helper type 1 anticandidal responses in mice. Infect. Immun. 70(12), 6621-6627 (2002
152. Mandel MA, Grace GG, Orsborn KI et al. The Cryptococcus neoformans gene DHA1 encodes an antigen that elicits a delayed-Type hypersensitivity reaction in immune mice. Infect. Immun. 68(11), 6196-6201 (2000
153. Biondo C, Beninati C, Delfino D et al. Identification and cloning of a cryptococcal deacetylase that produces protective immune responses. Infect. Immun. 70(5), 2383-2391 (2002
154. Biondo C, Beninati C, Bombaci M et al. Induction of T helper type 1 responses by a polysaccharide deacetylase from Cryptococcus neoformans. Infect. Immun. 71(9), 5412-5417 (2003
155. Huang H, Ostroff GR, Lee CK, Specht CA, Levitz SM. Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded beta-glucan particles. MBio 1(3), pii: E00164-10 (2010
156. Huang H, Ostroff GR, Lee CK et al. Relative contributions of dectin-1 and complement to immune responses to particulate beta-glucans. J. Immunol. 189(1), 312-317 (2012
157. Hurtgen BJ, Hung CY, Ostroff GR, Levitz SM, Cole GT. Construction and evaluation of a novel recombinant T cell epitope-based vaccine against Coccidioidomycosis. Infect. Immun. 80(11), 3960-3974 (2012
158. Kakeya H, Udono H, Maesaki S et al. Heat shock protein 70 (hsp70) as a major target of the antibody response in patients with pulmonary cryptococcosis. Clin. Exp. Immunol. 115(3), 485-490 (1999
159. Kakeya H, Udono H, Ikuno N et al. A 77-kilodalton protein of Cryptococcus neoformans, a member of the heat shock protein 70 family, is a major antigen detected in the sera of mice with pulmonary cryptococcosis. Infect. Immun. 65(5), 1653-1658 (1997
160. Young M, Macias S, Thomas D, Wormley FL Jr. A proteomic-based approach for the identification of immunodominant Cryptococcus neoformans proteins. Proteomics 9(9), 2578-2588 (2009
161. Robbins N, Uppuluri P, Nett J et al. Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog. 7(9), e1002257 (2011
162. Cowen LE. Hsp90 orchestrates stress response signaling governing fungal drug resistance. PLoS Pathog. 5(8), e1000471 (2009
163. Singh SD, Robbins N, Zaas AK, SchellWA, Perfect JR, Cowen LE. Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog. 5(7), e1000532 (2009
164. Cowen LE, Lindquist S. Hsp90 potentiates the rapid evolution of new traits: Drug resistance in diverse fungi. Science 309(5744), 2185-2189 (2005